13,677 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 13,677 shares of the biopharmaceutical company’s stock, valued at approximately $1,070,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC raised its position in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the last quarter. Larson Financial Group LLC grew its stake in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares in the last quarter. MidFirst Bank purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $28,000. Finally, Quantbot Technologies LP acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $30,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on HALO shares. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Finally, TD Cowen raised their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock worth $5,226,496 over the last ninety days. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $105.35 on Friday. The firm’s 50 day moving average price is $87.01 and its 200-day moving average price is $74.78. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $109.66. The firm has a market cap of $11.96 billion, a P/E ratio of 31.45, a P/E/G ratio of 0.42 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter last year, the company posted $1.54 EPS. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.